Tardive dyskinesia – Causes, symptoms, and management

Tardive dyskinesia – Causes, symptoms, and management

Tardive dyskinesia (TD) is a complex neurological disorder characterized by involuntary and repetitive movements of various body parts, most commonly the face, neck, and trunk. These abnormal movements often occur as a side effect of certain treatments. Other factors can contribute to its development as well. It has a multitude of causative factors. Understanding these causes is vital for healthcare providers and individuals alike, ultimately aiming to mitigate the impact of this challenging neurological disorder. Treatment-induced tardive dyskinesia The primary and most widely acknowledged cause of tardive dyskinesia is the prolonged use of certain treatment options. These treatments are typically prescribed to manage psychiatric conditions like schizophrenia, bipolar disorder, and severe depression. Unfortunately, while they can be effective in treating these conditions, long-term use can lead to the development of TD. Other risk factors While treatment use is the dominant cause, several additional risk factors can contribute to an individual’s susceptibility to tardive dyskinesia: Age: Older adults are at a higher risk of developing TD. This may be due to age-related changes in brain structure and function, making them more vulnerable to treatment effects. Genetics: Genetic factors can influence an individual’s likelihood of developing TD. Some people may have a genetic predisposition that makes them more susceptible when exposed to triggering treatment options.
Read More
Novavax vaccine – Development, safety, and usage for 12-17 age group

Novavax vaccine – Development, safety, and usage for 12-17 age group

The Novavax COVID-19 vaccine, known as NVX-CoV2373, has gained prominence for its usefulness and safety. Originally authorized for adults aged 18 and over, it recently received FDA approval for emergency use in adolescents between 12 and 17. This vaccine defends against COVID-19 with an innovative protein-based technology. An expansion of usage means a broader age group can benefit from the protection, bolstering efforts to curb the pandemic’s spread and keep younger populations safe. Additional approval from FDA The FDA granted the Novavax COVID-19 emergency use authorization for adolescents aged 12 to 17, endorsing it as a two-dose primary series. Additionally, the CDC director issued a decision memo permitting the use of the Novavax COVID vaccine as a primary series choice for this adolescent group. The availability of a vaccine option designed using conventional protein-based technology is seen as a benefit. Experts believe the vaccination rates may rise, especially since children are back to school and socializing. In related news, Novavax also worked on actively developing an updated version of its vaccine, tailored to target a specific variant of the virus and its offshoots. The company was looking forward to seeking authorization for this variant-targeting vaccine last year. Development and safety of the vaccine The development and safety of the Novavax COVID-19 vaccine for adolescents aged 12 to 17 have been carefully scrutinized and confirmed through comprehensive clinical trials.
Read More